IDH1 mutation

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM,[...]

By sjmartinez • December 20, 2024

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1) acute myeloid leukemia (AML)

Cortes J, Jonas BA, Schiller G, Mims A, Roboz GJ, Wei AH, Montesinos P, Ferrell PB, Yee KW, Fenaux P, Schwarer A, Watts JM. Olutasidenib[...]

By sjmartinez • March 28, 2024